Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
Inclusion Criteria: * 1\. Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension. 2\. Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for a minimum of 2-6 weeks. 3\. Able to move from current topical glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for a minimum of 4 weeks or longer based on FDA recommended washout per drug classification prior to Visit 3. 4\. Experience conjunctival redness as graded on the Efron scale of at least grade 2 after minimum of 4 weeks on netarsudil 0.02%/latanoprost 0.005% mono-therapy or longer bas…
Lumify is an approved eye drop to minimize ocular hyperemia.
Arctuva estimate
Verify or correct the compensation shown for this listing.